Sars-Cov-2-Antikörper und Verfahren zur Verwendung davon

Details

Veröffentlichungs-Nr.

EP4772194

Anmeldetag

28. April 2023

Veröffentlichung

8. Juli 2026

Rechtsraum

EP

IPC

A61K39/395

Abstract

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.

Anmelder

Firma

AstraZeneca UK Limited

Land

🇬🇧 Großbritannien